bio concept art
Viral Vectors Viral Vector Platform Adenovirus Manufacturing

SKyvec™ Adenovirus Manufacturing for Advanced Therapies

Advance your adenovirus program with scalable development and manufacturing built for clinical and commercial success. SK pharmteco supports adenoviral vector production across first-generation and helper-dependent (HDAd, “gutless”) systems, from virus banks through drug substance and drug product. Our adaptive platform combines high-yield upstream production with a streamlined downstream process that improves recovery, reduces operational complexity, maintains high purity, and supports regulatory-ready performance.

With global CGMP operations, flexible starting materials, and integrated analytical support, we help programs progress efficiently from early development to commercial supply across gene therapy, vaccines, and oncolytic applications to meet your program’s needs.

Contact us

Why SK pharmteco

Successful adenovirus programs are defined early. Decisions around construct design, cell line selection, and infection strategy directly affect yield, scalability, and regulatory readiness.
Processes are designed to scale without re-engineering by focusing on:

  • Adaptive platform built for adenoviral vector development, structured enough to accelerate progress
  • Suspension-based production for consistent, high-yield scale-up
  • Early alignment of critical quality attributes (CQAs)
  • Strategies to reduce replication-competent adenovirus (RCA) risk
  • Process architectures that maintain high performance across development stages

Adenoviral manufacturing rewards early insight. The sooner developers understand product behavior, process vulnerability, and the decisions that matter later, the better positioned they are to move with confidence from development to GMP. That is the conversation SK pharmteco welcomes.

Capabilities

Deep Vector Expertise

We support both first-generation and helper-dependent (“gutless”) adenoviral vectors, with experience across Ad5, simian serotypes, and oncolytic systems. This dual capability supports conventional and high-capacity HDAd vectors and complex payloads above 30 kb.
Many platforms specialize in one vector type. We build processes that work across both.

High-yield Upstream Production

Adenovirus production is driven by process design. Our suspension-based platform is designed for high-titer production at manufacturing scale up to 500 L, with reduced variability during scale-up and lower consumable usage.
The result is a process built for robust, scalable manufacturing.

Streamlined Downstream Processing

As upstream yields increase, downstream purification becomes the main constraint on yield and cost. SK pharmteco’s downstream architecture simplifies development (including membrane-based capture and FT polishing), minimizes cumulative product loss, maintains strong clearance of residual host-cell proteins and DNA, and preserves viral infectivity and capsid integrity.
This improves recovery, reduces buffer consumption, and shortens processing timelines without adding complexity.

Scale-Up and Tech Transfer

Alignment between early-stage optimization and manufacturing conditions enables efficient scale-up. MSAT-supported tech transfer ensures process control, consistency, and reliable performance across batches and production scales.

Integrated Analytical and CGMP Support

We support the full workflow from Master Virus Bank generation and process development through scalable CGMP manufacturing and CGMP release testing, including RCA detection. Integrated analytical capabilities support genome and capsid titer analysis, identity, impurity profiling, and stability characterization. These capabilities enable process control, consistent product characterization, and alignment with regulatory expectations across development and manufacturing.

Learn More

Built for Performance

Integrated upstream production, downstream purification, and analytical capabilities enable measurable improvements in yield, efficiency, and process simplicity across adenovirus manufacturing of both first-generation and helper-dependent (HDAd, gutless) systems.

Optimizing COGS in Adenovirus Manufacturing

Adenoviral vectors are a proven platform for gene therapy and vaccines, yet downstream purification often defines overall yield, cost, and operational efficiency. Cost optimization focuses on simplifying process architecture and improving recovery.

  • Downstream process simplification to minimize cumulative yield loss
  • Lower buffer consumption and shorter processing timelines
  • Improved recovery through membrane-based capture and FT polishing purification strategies
  • Scalable, single-use systems reducing operational complexity

These approaches enable more predictable manufacturing economics while maintaining high-quality vector production.

Adenovirus Manufacturing FAQs

Contact us

We’re committed to supporting your development and manufacturing needs. Complete the form and someone from SK pharmteco will be in touch shortly.